BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16061687)

  • 1. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
    Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
    Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
    Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
    Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
    Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
    Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
    Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
    J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
    Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
    Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
    Yamanaka R; Xanthopoulos KG
    DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with trifunctional nanoparticles that address CD8
    Shen L; Krauthäuser S; Fischer K; Hobernik D; Abassi Y; Dzionek A; Nikolaev A; Voltz N; Diken M; Krummen M; Montermann E; Tubbe I; Lorenz S; Strand D; Schild H; Grabbe S; Bros M
    Nanomedicine (Lond); 2016 Oct; 11(20):2647-2662. PubMed ID: 27628310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
    Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
    J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
    Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
    J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J; Brück J; Lenz J; Knop J; Tüting T
    Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
    Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.